GlassScriptPhysician profile
Joseph Washburne
NPI 1750354247
$7,595.38
in general payments reported to CMS, 2019-2025
27 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $3,277 · 2021: $3,261 · 2022: $304 · 2023: $234 · 2024: $246 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,192.55 | 2019-2023 | Da Vinci Surgical System |
| Abbvie INC. | $421.97 | 2019-2024 | Liletta, Lo Loestrin Fe |
| Pfizer INC. | $141.26 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $141.08 | 2022-2025 | |
| Avion Pharmaceuticals | $133.73 | 2019-2022 | |
| Hologic Sales and Service, LLC | $81.00 | 2020-2024 | Novasure, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $76.87 | 2019-2025 | |
| Ethicon US, LLC | $44.60 | 2022-2024 | Ethicon |
| Organon LLC | $35.74 | 2022-2025 | Jada System, Nexplanon |
| Teva Pharmaceuticals USA, INC. | $30.87 | 2019-2020 | |
| Evofem Biosciences, INC. | $30.21 | 2021 | |
| Coloplast Corp | $23.45 | 2019-2020 | |
| Exeltis, USA INC. | $22.55 | 2025 | Slynd |
| Agile Therapeutics, INC. | $20.07 | 2022 | |
| Smith+Nephew, INC. | $18.33 | 2024 | Pico 7 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $18.21 | 2024 | |
| Asensus Surgical, INC. | $17.82 | 2023 | Senhance |
| Axonics, INC. | $17.45 | 2021 | |
| Becton, Dickinson and Company | $16.92 | 2022 | |
| Novo Nordisk INC | $16.80 | 2022 | |
| Coopersurgical, INC. | $16.62 | 2022 | |
| Astellas Pharma US INC | $16.09 | 2023 | Veozah |
| Meditrina | $14.80 | 2023 | |
| Sumitomo Pharma America, INC. | $13.88 | 2023 | Myfembree |
| Minerva Surgical, INC | $11.74 | 2020 | |
| Therapeuticsmd, INC. | $11.63 | 2019 | |
| Medela LLC | $9.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Washburne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.